Log In
BCIQ
Print this Print this
 

Mabelio, Zevtera, ceftobiprole medocaril

Also known as: ceftobiprole (BAL5788) (formerly Zeftera)

  Manage Alerts
Collapse Summary General Information
Company Basilea Pharmaceutica AG
DescriptionProdrug of ceftobiprole, a broad-spectrum cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA)
Molecular Target
Mechanism of ActionPenicillin binding proteins (PBP) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPneumonia
Indication DetailsTreat community-acquired bacterial pneumonia (CABP); Treat community-acquired pneumonia (CAP); Treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Treat hospital-acquired pneumonia (HAP); Treat nosocomial pneumonia; Treat pneumonia in the hospital setting; Treat severe pneumonia in the hospital setting
Regulatory Designation U.S. - Qualified Infectious Disease Program (Treat community-acquired bacterial pneumonia (CABP));
U.S. - Qualified Infectious Disease Program (Treat community-acquired pneumonia (CAP));
EU - Standard Review (Treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP));
EU - Standard Review (Treat severe pneumonia in the hospital setting);
Switzerland - Standard Review (Treat community-acquired pneumonia (CAP));
Switzerland - Standard Review (Treat hospital-acquired pneumonia (HAP))
PartnerHikma Pharmaceuticals plc;
Quintiles Transnational Holdings Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/15/2015

Undisclosed

Undisclosed

Undisclosed

07/21/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today